SHANGHAI MICURX PHARMACEUTICAL CO., LTD. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 4.35 CNY | +3.82% |
|
-3.97% | -33.38% |
Valuation
| Fiscal Period: December | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|
| Capitalization 1 | 5,805 | 4,279 | 2,850 | - | - |
| Enterprise Value (EV) 1 | 5,805 | 4,279 | 2,850 | 2,850 | 2,850 |
| P/E ratio | -23.3 x | -10.2 x | -6.74 x | -6.96 x | -12.1 x |
| Yield | - | - | - | - | - |
| Capitalization / Revenue | 120 x | 47.1 x | 17.7 x | 11.2 x | 7.34 x |
| EV / Revenue | 120 x | 47.1 x | 17.7 x | 11.2 x | 7.34 x |
| EV / EBITDA | -26.2 x | -10.6 x | -7.75 x | -9.69 x | - |
| EV / FCF | - | -12.7 x | -6.16 x | -7.46 x | -6.93 x |
| FCF Yield | - | -7.87% | -16.2% | -13.4% | -14.4% |
| Price to Book | 4.79 x | 5.13 x | 34.8 x | -4.22 x | 19.8 x |
| Nbr of stocks (in thousands) | 655,210 | 655,210 | 655,210 | - | - |
| Reference price 2 | 8.860 | 6.530 | 4.350 | 4.350 | 4.350 |
| Announcement Date | 23-02-24 | 24-02-22 | - | - | - |
1CNY in Million2CNY
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|
| Net sales 1 | 7.66 | 48.21 | 90.78 | 161 | 255.5 | 388.5 |
| EBITDA 1 | - | -221.4 | -405.2 | -368 | -294 | - |
| EBIT 1 | - | -222.9 | -410.9 | -418 | -405.5 | -235 |
| Operating Margin | - | -462.46% | -452.65% | -259.63% | -158.71% | -60.49% |
| Earnings before Tax (EBT) 1 | - | -220.3 | -415.2 | -419.5 | -407 | -234 |
| Net income 1 | -226.3 | -220.3 | -421.1 | -423.2 | -410.6 | -234.1 |
| Net margin | -2,953.92% | -456.99% | -463.91% | -262.86% | -160.7% | -60.25% |
| EPS 2 | - | -0.3800 | -0.6400 | -0.6450 | -0.6250 | -0.3600 |
| Free Cash Flow 1 | - | - | -336.7 | -463 | -382 | -411 |
| FCF margin | - | - | -370.96% | -287.58% | -149.51% | -105.79% |
| FCF Conversion (EBITDA) | - | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - | - |
| Dividend per Share | - | - | - | - | - | - |
| Announcement Date | 22-07-18 | 23-02-24 | 24-02-22 | - | - | - |
1CNY in Million2CNY
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|
| Net Debt | - | - | - | - | - | - |
| Net Cash position | - | - | - | - | - | - |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - |
| Free Cash Flow 1 | - | - | -337 | -463 | -382 | -411 |
| ROE (net income / shareholders' equity) | - | -29.5% | -41.1% | -125% | -440% | -160% |
| ROA (Net income/ Total Assets) | - | -20.5% | -31.2% | -41.2% | -41.5% | -33.7% |
| Assets 1 | - | 1,073 | 1,349 | 1,028 | 990.6 | 694.5 |
| Book Value Per Share 2 | - | 1.850 | 1.270 | 0.1300 | -1.030 | 0.2200 |
| Cash Flow per Share 2 | - | -0.3700 | -0.5000 | -0.6600 | -0.5600 | -0.3700 |
| Capex 1 | - | 10.7 | 7.66 | 20.5 | 13 | 10.5 |
| Capex / Sales | - | 22.15% | 8.44% | 12.73% | 5.09% | 2.7% |
| Announcement Date | 22-07-18 | 23-02-24 | 24-02-22 | - | - | - |
1CNY in Million2CNY
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
4.35
CNY
Average target price
6.875
CNY
Spread / Average Target
+58.05%
EPS Revisions
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -33.38% | 392M | |
| +55.32% | 815B | |
| -6.75% | 352B | |
| +13.56% | 314B | |
| +10.68% | 303B | |
| +16.57% | 242B | |
| +2.04% | 224B | |
| +13.31% | 218B | |
| +8.48% | 168B | |
| -2.81% | 159B |
- Stock Market
- Equities
- 688373 Stock
- Financials Shanghai MicuRx Pharmaceutical Co., Ltd.
